Key Highlights

  • First ROXUS prescriptions fulfilled in the US subsequent to quarter end, through Shed's Mavrox telehealth platform and Strive Pharmacy, less than three months after definitive agreements were executed
  • Final Phase II report confirms SPONTAN's six-fold faster absorption than oral vardenafil tablets, completing the FDA pharmacokinetic dataset; Phase III study targeted for 1H CY2027
  • 147-patient real-world study reports 93% response rate among men seeking greater convenience and spontaneity, 64% in post-prostatectomy patients, and 68% overall
  • Ended Q1 FY27 with A$18.2 million cash, debt-free, and net operating cash outflow of A$1.6 million

From Agreements to Patient Prescriptions

LTR Pharma Limited (ASX:LTP) has reported a quarterly period — ending 30 September 2026 — that the company itself characterised as a shift from implementation to patient service. The headline development, arriving just after quarter end on 6 October 2026, was the fulfilment of the first patient-specific ROXUS prescriptions in the United States, received through Shed's Mavrox telehealth platform and dispensed by Strive Pharmacy. That milestone arrived less than three months after the definitive commercial agreements with both parties were executed in July 2026.

The speed of that transition — from signed agreements to dispensed prescriptions — is a meaningful operational data point for a pharmaceutical company navigating the Section 503A compounding pathway in the US market. It demonstrates that the commercial infrastructure assembled across the quarter functioned as designed from the outset.

SPONTAN Phase II Complete, Phase III Timeline Set

The other headline development from the period concerns SPONTAN, LTR Pharma's intranasal vardenafil product targeting multiple therapeutic applications. The final Phase II report, completed subsequent to quarter end on 1 October 2026, confirmed SPONTAN's six-fold faster absorption compared to oral vardenafil tablets. That result completes the pharmacokinetic dataset agreed with the US FDA, a prerequisite for advancing toward Phase III.

The company has set a target of commencing Phase III by the first half of calendar year 2027. Executive Chairman Lee Rodne described the company's approach as disciplined Capital allocation, supporting US partners in building ROXUS prescription activity while progressing the submission-enabling workstreams for SPONTAN in parallel.

For a dual-product men's health platform, the ability to advance SPONTAN's regulatory pathway while simultaneously driving ROXUS commercial adoption represents a potential source of diversified news flow through 2027.

Real-World Evidence and Australian Market

LTR Pharma also reported results from a 147-patient real-world study that provides insight into patient response rates for its intranasal technology. The study reported a 93% response rate among men seeking greater convenience and spontaneity with their erectile dysfunction treatment — a segment increasingly targeted by telehealth operators. In the clinically challenging post-prostatectomy patient group, the response rate was 64%, and the overall cohort response was 68%.

These results feed into the company's market positioning and commercial messaging for ROXUS in the US as prescribing activity builds through the Mavrox platform.

In Australia, SPONTAN surpassed 2,000 bottles dispensed as at 20 October 2026, delivered under TGA Special Access Scheme and Authorised Prescriber pathways, with more than 120 clinicians having prescribed SPONTAN on more than one occasion — an indicator of repeat clinical adoption rather than one-off trial prescribing.

Sector Context

The men's health pharmaceutical sector, and specifically the telehealth-enabled erectile dysfunction market, has seen material growth driven by the normalization of digital prescribing and home delivery models. Intranasal formulations offer a differentiated patient experience relative to oral tablets, with faster onset representing a clinically and commercially relevant distinction for patients seeking spontaneity. LTR Pharma's entry into the US via the Section 503A compounding route provides an early commercial pathway ahead of potential full NDA approval for SPONTAN.

Risks

The primary near-term risk is the pace at which ROXUS prescription volumes build through the Mavrox and Strive Pharmacy channels. Early commercial adoption through telehealth platforms can be difficult to predict, and the company has noted it will provide further updates as meaningful information becomes available — suggesting prescription Volume visibility remains limited at this stage. The SPONTAN Phase III programme will also require ongoing capital deployment, and the submission-enabling workstreams (CMC package finalisation, human factors validation, leachables testing, non-clinical toxicology) each carry their own execution timelines.

What to Watch Next

ROXUS prescription activity through the US commercial framework will be the primary commercial metric to watch. Any update on SPONTAN Phase III commencement — targeted for 1H CY2027 — will be an important regulatory milestone. The investigator-initiated SPONTAN study in pulmonary arterial hypertension, for which ethics approval was received subsequent to quarter end, also represents a potential indication expansion pathway worth tracking.